report offers an integrated view of epidemiological trends, treatment approaches, unmet needs present in the treatment market, and the pipeline therapies expected to have a tremendous impact in the Hemophilia A market in the coming next decade in the 7MM (the US, EU5 (the UK, Germany, Spain, Italy, and France), and Japan).
The Hemophilia A Market report offers a detailed mapping of the key companies at the forefront of the domain, major collaborations, deals, and tie-ups taking place, as well as clinical trials, and recent happenings ongoing in the Hemophilia A market landscape.
The mainstay treatment option has long been
Share it
The toxic globules of sugar and fat slowly pile up in the body s cells, accumulating in blood vessels and in major organs like the kidney and heart.
Typically, special-purpose proteins within the cell would tear apart and break down the toxins. But for people with Fabry, a rare inherited disease, genetic mutations result in garbled, sometimes missing, instructions for constructing the right proteins.
Without the right disposal tools, cells are helpless to the inexorable buildup of the dangerous molecules. The first warning signs are as varied as they are acute: burning sensations of pain in the hands and feet, abnormally low sweat production and dark skin rashes. Over time, for those most severely affected, symptoms can become dire, leading to organ dysfunction and early death.
Posted on 524
Shasqi, a clinical-stage biotechnology company developing precision activated oncology therapeutics with its proprietary Click Activated Protodrugs Against Cancer (CAPAC
TM) platform, announced today the members of its strategic advisory board, which bring a range of expertise to the company including corporate strategy, clinical development, cellular biology, and cancer therapeutics.
“Shasqi has made important progress during the last year with the initiation of our phase 1 clinical trial of SQ3370 and the advancement of our CAPAC drug development platform we’re preparing for the next phase of our growth,” said José M. Mejía Oneto, M.D., Ph.D., Founder and CEO of Shasqi. “We’ve deliberately selected and cultivated a team of strategic advisors with the skills, expertise and experience to help us navigate through the opportunities ahead of us and, ultimately, position us to benefit as many peop
Dyve Biosciences Appoints Camilla V. Simpson to Board of Directors
Dyve Biosciences Appoints Camilla V. Simpson to Board of Directors
THOUSAND OAKS, Calif., Feb. 01, 2021 Dyve Biosciences, Inc. (“Dyve”), a clinical stage biotechnology company, today announced that Camilla V. Simpson has joined Dyve’s Board of Directors.
Ryan Beal, M.D., Chief Executive Officer of Dyve, stated: “We are delighted to have Camilla join our board during this exciting time for Dyve. Our lead candidate, DYV700, in Phase 2 clinical development, has shown best-in-class potential for the treatment of acute gout flares and is on track for completion of Phase 2 in the first half of this year. With DYV700 and our emerging pipeline of additional Phase 2 candidates, Camilla’s wealth of leadership experience in product strategy, portfolio management, regulatory affairs, and business development will be invaluable as we continue to build momentum. We look forward to Camilla’s immediate contribution
Virtual Analytical Summit 2021: Full meeting agenda
Editorial Article: Virtual Analytical Summit 2021: Full meeting agenda
Watch world-leading scientists and industry experts online, February 23-24, to discover next-generation technologies to advance your research
17 Feb 2021
The full exciting schedule has been announced for the SelectScience
Covering a diverse range of technologies, applications and topics spanning the fields of food security, materials, life sciences, pharma, biopharma and more, this groundbreaking online event will feature talks by an outstanding lineup of world-leading speakers and top manufacturers, as well as live Q&As, virtual resource hubs and dedicated networking sessions – all completely free of charge.
Among those invited to present will be Dr. Diane Turner, Anthias Consulting Ltd, who highlights the significance of the event: I think it s really important for the analytical science community to continue to connect during these challenging